Under-reporting of serious adverse drug reactions in Sweden

被引:91
作者
Bäckström, M [1 ]
Mjörndal, T [1 ]
Dahlqvist, R [1 ]
机构
[1] Umea Univ Hosp, Div Clin Pharmacol, S-90185 Umea, Sweden
关键词
adverse drug reaction; spontaneous reporting; under-reporting;
D O I
10.1002/pds.962
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction Adverse drug reactions (ADR) constitute a major problem, both from a medical point of view and as an economical burden. Spontaneous reporting of ADRs is one of the methods for post marketing surveillance of drug safety. Under-reporting can also provide an important obstacle to rapid and relevant signal detection. Aim To investigate the rate of under-reporting serious ADRs of selected ICD 10 diagnoses. Method In order to investigate the under-reporting rate we investigated at five hospitals within the county of Norrbotten in Sweden the total number of diagnosed cases during a period of 5 years (1996-2000) with the following diagnoses: cerebral haemorrhage (I 61.0- I 61.9), pulmonary embolism (I 26.0 and I 26.9), embolism or thrombosis (I 74.0-I 74.9), phlebititis, thrombophlebitits or venous thrombosis (I 80.0-I 80.3, I80.8 and I 80.9) and portal vein thrombosis and other thrombosis or emboli (I 82.0-I 82.3, I 82.8 and I 82.9). The identity of these patients was obtained through a database search. The patients' case records were then scrutinized by a specially trained nurse and the drugs used at the time of the event were noted. An assessment of the possibility of an ADR was performed using standard WHO causality criteria. Later, database search in the Swedish ADR registry was performed in order to investigate whether these suspected ADRs had been reported to the national authority in Sweden or not. Results In total 1349 case records were found and scrutinized. Of these, 107 patients had received drugs that could have been a probable or possible cause to the diagnoses. Of these 92 cases had not been reported and only 15 patients were found in the database, giving an overall under-reporting rate of all ADRs of 86%. The most commonly occurring diagnoses were cerebral haemorrhage followed by venous thrombosis, 545 and 468 respectively. Among those cases that should have been reported according to the existing rules for spontaneous reporting of suspected ADRs the most frequently occurring diagnosis was cerebral haemorrhage (I 61.0) in connection to treatment with anticoagulants. Conclusion The rate of spontaneous ADR reporting is very low, also for serious and fatal reactions. Copyright (C) 2004 John Wiley Sons, Ltd.
引用
收藏
页码:483 / 487
页数:5
相关论文
共 26 条
[1]   Under-reporting of adverse drug reactions -: Estimate based on a spontaneous reporting scheme and a sentinel system [J].
Alvarez-Requejo, A ;
Carvajal, A ;
Bégaud, B ;
Moride, Y ;
Vega, T ;
Arias, LHM .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (06) :483-488
[2]   Attitudes to reporting adverse drug reactions in northern Sweden [J].
Bäckström, M ;
Mjörndal, T ;
Dahlqvist, R ;
Nordkvist-Olsson, T .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (9-10) :729-732
[3]   Spontaneous reporting of adverse drug reactions by nurses [J].
Bäckström, M ;
Mjörndal, T ;
Dahlqvist, R .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2002, 11 (08) :647-650
[4]  
BELTON JK, 1995, BR J CLIN PHARM, P223
[5]   Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union [J].
Belton, KJ ;
Gram, LF ;
Royer, RJ ;
Feely, J ;
McGettigan, P ;
Velo, GP ;
Conforti, A ;
Leone, R ;
Stricker, BHC ;
Teixeira, F ;
Laporte, JP ;
Capella, D ;
Beermann, B ;
Lewis, SC ;
Payne, S ;
Rawlins, MD ;
Wood, SM .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (06) :423-427
[6]   DRUG-RELATED PROBLEMS CAUSING ADMISSION TO A MEDICAL CLINIC [J].
BERGMAN, U ;
WIHOLM, BE .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 20 (03) :193-200
[7]   Incidence and costs of adverse drug reactions during hospitalisation - Computerised monitoring versus stimulated spontaneous reporting [J].
Dormann, H ;
Muth-Selbach, U ;
Krebs, S ;
Criegee-Rieck, M ;
Tegeder, I ;
Schneider, HT ;
Hahn, EG ;
Levy, M ;
Brune, K ;
Geisslinger, G .
DRUG SAFETY, 2000, 22 (02) :161-168
[8]  
EINARSON TR, 1993, ANN PHARMACOTHER, V27, P833
[9]  
Eland IA, 1999, BRIT J CLIN PHARMACO, V48, P623
[10]  
FLETSCHER AP, 1992, ADVERSE DRUG REACT T, V11, P211